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Staphylococcus aureus (S. aureus) can secrete a broad range of virulence factors,
among which staphylococcal serine protease-like proteins (Spls) have been identified
as bacterial allergens. The S. aureus allergen serine protease-like protein D (SplD)
induces allergic asthma in C57BL/6J mice through the IL-33/ST2 signaling axis. Analysis
of C57BL/6J, C57BL/6N, CBA, DBA/2, and BALB/c mice treated with intratracheal
applications of SplD allowed us to identify a frameshift mutation in the serine (or
cysteine) peptidase inhibitor, clade A, and member 3I (Serpina3i) causing a truncated
form of SERPINA3I in BALB/c, CBA, and DBA/2 mice. IL-33 is a key mediator of
SplD-induced immunity and can be processed by proteases leading to its activation
or degradation. Full-length SERPINA3I inhibits IL-33 degradation in vivo in the lungs of
SplD-treated BALB/c mice and in vitro by direct inhibition of mMCP-4. Collectively, our
results establish SERPINA3I as a regulator of IL-33 in the lungs following exposure to
the bacterial allergen SplD, and that the asthma phenotypes of mouse strains may be
strongly influenced by the observed frameshift mutation in Serpina3i. The analysis of
this protease-serpin interaction network might help to identify predictive biomarkers for
type-2 biased airway disease in individuals colonized by S. aureus.
Keywords: allergy, asthma, IL-33, S. aureus, SplD, type 2 immunity
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INTRODUCTION
Several type 2 airway diseases, such as allergic rhinitis, chronic
rhinosinusitis with nasal polyps, and allergic asthma are
associated with nasal colonization by Staphylococcus aureus
(S. aureus) (1, 2). S. aureus can secrete a wide range of
virulence factors, among which staphylococcal serine protease-
like proteins (Spls) have been identified as bacterial allergens
and inducers of allergic asthma in C57BL/6J mice by activating
the IL-33/ST2 signaling axis (3, 4). Spl-specific IgE levels are
increased in asthmatic patients compared to healthy controls,
and detectable amounts of Spls have been found in nasal
polyp tissue (3, 4). Strikingly, 25–30% of the general population
are persistently colonized with S. aureus and up to 69% are
intermittent or occasional S. aureus carriers (5). Even though
there is strong evidence for S. aureus being an inducer, enhancer,
and driver of chronic inflammatory airway diseases (3, 6–9),
it is not understood why not all persistent S. aureus carriers
develop a chronic inflammatory response toward it. Since
S. aureus exposure on its own cannot explain the pathogenesis, a
genetic predisposition might be underlying the response toward
S. aureus.
IL-33 is an innate cytokine of the IL-1 family, which is
expressed in epithelial, endothelial (10), and smooth muscle
cells (11), as well as in fibroblasts, activated mast cells (12),
and dendritic cells (13), and released upon allergen exposure or
during necrosis (14, 15). IL-33 mediates Th2 cytokine production
in innate lymphoid cells type 2 (ILC2s), Th2 cells, and invariant
natural killer T cells by binding to its membrane bound receptor
ST2 (13, 16–19). Like other IL-1 cytokine family members, the
cytokine activity of IL-33 can be regulated by proteolytic cleavage
(20). When it is cleaved by endogenous proteases or proteolytic
allergens in the cleavage/activation domain, the cytokine activity
of IL-33 is increased (21–25). Inactivation of IL-33 occurs by
cleavage in the IL-1-like cytokine domain through endogenous
proteases such as the human neutrophil proteinase 3, the human
mast cell chymase and the murine chymase mouse mast cell
protease 4 (mMCP-4), or by the caspases 3 and 7 in humans and
mice (26–29).
Endogenous protease activity is, in turn, under tight regulation
of serine protease inhibitors, such as serpins. Serpins inhibit
proteases with their C-terminal reactive center loop (RCL). Upon
cleavage in the RCL, they form SDS-stable complexes with their
target proteases by covalent binding (30). The murine Serpina3i
is expressed at low levels in the lungs, thymus, and spleen during
homeostasis (31).
In the present study we have identified SERPINA3I as a
novel regulator of IL-33 processing in a murine asthma model.
Interestingly, BALB/c mice carry a frameshift mutation in the
Serpina3i gene, leading to faster cleavage of IL-33 upon serine
protease-like protein D (SplD) exposure. This observation may
explain the lack of a type 2 inflammatory response upon SplD
challenge of the lungs. Our results suggest that SERPINA3I is
important for controlling inflammatory reactions in mice.
The aim of this study was to find the underlying genetic
difference between BALB/c and C57BL/6J mice leading to the
different response toward SplD.
MATERIALS AND METHODS
Recombinant Protein Production
Recombinant SplD was produced in the Bacillus subtilis strain
6051HGW LS8P-D, which lacks the proprietary proteases
WprA, Epr, Bpr, NprB, NprE, Vpr, Mpr, and AprE, as
previously described in detail (3, 4). SplD was purified
from the cell-free supernatants by means of ion-exchange
chromatography on an SP Sepharose Fast Flow column (GE
Healthcare, Fairfield, CT, United States), followed by a 2-
step purification with centrifugal filter units (Amicon Ultra
30K/10K, Merck Millipore, Billerica, MA, United States). The
buffer was exchanged to PBS and the quality of the native
SplD preparation was verified by using SDS-PAGE. Recombinant
full-length, C-terminal HIS tagged SERPINA3I (isoform X3;
NCBI reference sequence: XP_017170642.1) was produced in
HEK293 cells by ProSpec-Tany Technogene Ltd. (Rehovot,
Israel). The purified protein was endotoxin low (<0.01 EU/µg)
and provided in PBS. Proteolytically active mMCP-4 was
produced and activated essentially as previously described in
Andersson et al. (32).
Mice and Treatment Protocols
Female C57BL/6JRj (C57BL/6J), C57BL/6NRj (C57BL/6N),
BALB/cJRj (BALB/c), CBA/JRj (CBA), and DBA/2 JRj
(DBA/2) wild-type mice (Janvier Labs, Saint-Berthevin
Cedex, France) were 6–8 weeks old during the treatment
protocols. Animals were kept under standard conditions,
in the individually ventilated (IVC) cages, 12 h light/dark
cycle, access to food and water ad libitum. All animal
experiments were approved by the local ethics committees
of Ghent University.
For the short-term treatment, mice were treated with an
intratracheal (i.t.) application of either 50 µL PBS or 50 µg
SplD in 50 µL PBS once and euthanized 6 or 12 h after
the single treatment. For the long-term sensitization protocol,
C57BL/6J, C57BL/6N, CBA, DBA/2, and BALB/c mice were
treated with six i.t. applications of either 50 µL PBS (Gibco,
Erembodegem, Belgium) or 45 µg SplD in 50 µL PBS with one
additional application of 50 µL PBS every 2 days. Additional
groups of BALB/c mice were treated with either 50 µL PBS and
200 ng murine IL-33 (Peprotech, Rocky Hill, NJ, United States)
in 50 µL PBS or with 45 µg SplD in combination with
200 ng of IL-33 in 50 µL PBS (SplD + IL-33) in the same
manner as the other treatment groups. All mice underwent light
anesthesia by inhalation of isoflurane/air (Ecuphar, Oostkamp,
Belgium) during every application. 48 h after the last i.t.
application, mice were euthanized with an intraperitoneal
injection of 100 µL nembutal (Ceva Santé Animale, Libourne,
France). For the reconstitution of SERPINA3I BALB/c, mice
received 50 µg SplD in combination with 5 µg SERPINA3I
(SplD + SERPINA3I), or sole 5 µg SERPINA3I, and were
euthanized after 12 h. Serum, bronchoalveolar lavage fluid
(BALF) and lungs were collected and processed as previously
described (4). All experimental protocols are summarized in
Supplementary Table 2.
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Organ Processing
Blood was collected in EDTA Microvettes 200Z (Sarstedt,
Nümbrecht, Germany) and centrifuged for 10 min at 3000 rpm.
Serum was collected and stored at -20◦C before further
analysis. BALF was collected by rinsing the airways three
times with 0.3 mL of 1% bovine serum albumin (BSA; Sigma
Aldrich, Diegem, Belgium) in PBS with complete protease
inhibitor cocktail (Roche Diagnostics, Anderlecht, Belgium)
and twice with 1 mL of 0.2% EDTA (Sigma-Aldrich) in PBS
and kept at 4◦C. Red blood cells were lysed for 2 min
with VersaLyse buffer (Beckman Coulter, Krefeld, Germany),
and BALF cells were used for flow cytometry analysis.
The left lobe of the perfused lungs was fixed with 10%
formalin (Sigma-Aldrich) for paraffin embedding, while the
right lobes were either snap-frozen or minced and digested
with 1 mg/mL collagenase type II (Worthington Biochemical,
Lakewood, NJ, United States) for flow cytometry analysis. Snap-
frozen lungs were either used for protein or RNA extraction.
For protein extraction, they were homogenized by using
the Tissue Lyser LT (Qiagen, Antwerp, Belgium) for 2 min
at 50 oscillations/s with 10 times more w/v T-Per Tissue
Protein Extraction Reagent (Thermo Fisher Scientific) with
HALT protease inhibitor cocktail kit (Thermo Fisher Scientific).
After 10 min of centrifugation at 3000 rpm, supernatants
were collected and repeatedly centrifuged at 15,000 rpm for
three in each. The total protein concentration of the lung
homogenates was determined with the Bio-Rad Protein assay
(Bio-Rad Laboratories, Hercules, CA, United States) in the
collected supernatants.
Western Blotting
Thirty µg protein of lung homogenates were denatured
for 10 min at 95◦C with sample buffer under reducing
conditions (sample buffer: Laemmli buffer with 5% β-mercapto-
ethanol and 0.25% Bromophenol blue) and loaded on 4–
15% mini-PROTEAN TGX Stain-Free Protein gels (Bio-
Rad), separated by means of SDS-PAGE and transferred to
a nitrocellulose membrane (Bio-Rad). For Western Blotting,
mouse IL-33 antigen affinity-purified polyclonal goat IgG
(dilution 1:300; R&D Systems) antibody was used with polyclonal
peroxidase labeled anti-goat IgG (H + L; 1:1000; Vector
Laboratories Inc., Burlingame, CA, United States); and mouse
anti β-actin primary antibody, clone AC-74 (1:5000; Sigma-
Aldrich), was used with polyclonal peroxidase labeled anti-
mouse IgG (1:2000; Invitrogen). Bands were visualized with
the Immobilon Western Chemiluminescence HRP substrate
(Merck Millipore). Semiquantitative analysis of band intensities
was performed by measuring the area under the peak of
plotted lanes with the ImageJ software (National Institutes of
Health, Bethesda, MD, United States). For all Western blot
quantifications, n = 4.
Luminex
Concentrations of murine IL-4, IL-5, and IL-13, and IL-33 in
lung homogenates were analyzed by using Luminex Performance
assays (R&D Systems, Abingdon, United Kingdom).
Periodic Acid–Schiff Staining
Deparaffinized and rehydrated 5-µm lung sections were stained
for mucus producing goblet cells by using the periodic acid–Schiff
kit (Sigma-Aldrich). Positively stained cells in airway with a
perimeter between 800 and 2000 µm were counted using the cell
counting tool in ImageJ.
Total IgE and SplD-Specific IgE ELISA
Total serum IgE was measured with the Mouse IgE Ready-Set-
Go! ELISA Kit (affymetrix eBioscience, Vienna, Austria). The
SplD-specific IgE ELISA was performed as described previously
in detail by coating the plates with 5 µg/mL SplD, and specific
IgE was measured in serum.
Flow Cytometry
The following antibodies were used for identification of immune
cells: anti-mouse CD16/CD32 clone 93 (eBioscience), Gr1-
FITC (Ly-66) clone RB6-8C5 (eBioscience), SiglecF-PE clone
ES22-10D8 (Miltenyi Biotec, Bergisch Gladbach, Germany),
CD11b–peridinin-chlorophyll-protein complex (PerCP)–Cy5.5
(eBioscience), F4/80-APC (BD Biosciences), CD8a-PerCp-
Cy5.5 clone 53-6.7 (eBioscience), CD4-FITC clone RM4-4
(eBioscience), MHCII clone M5/114.15.2 FITC (eBioscience),
CD11c PE-Cy7 clone HL3 (eBioscience), and LIVE/DEAD
Fixable Near-IR Dead Cell Stain Kit (Thermo Fisher Scientific).
Cells were stained for 30 min at room temperature and washed
with PBS; LIVE/DEAD Fixable Near-IR Dead Cell Stain Kit
(Thermo Fisher Scientific) was used for 10 min to exclude dead
cells. Cells were washed and analyzed by using flow cytometry
with the FACS Canto II (BD Biosciences).
RT-qPCR Analysis of mIL-33 and
Serpina3i Expression
For RNA extraction, cells were lysed with RLT buffer (Qiagen),
or frozen lung tissues were ground in liquid nitrogen, prior
to lysis in RLT (Qiagen). Lysed lung tissues were loaded
on the QIAshredder Mini Spin Columns (Qiagen). The RNA
was extracted from the cell lysate or QIAshredder Mini Spin
Columns eluate following the manufacturer’s instructions of the
RNeasy Mini Kit (Qiagen). DNA was digested using the RNase-
Free DNase Set (Qiagen). RNA concentrations were measured
with Nanodrop, and cDNA was synthesized with the iScriptTM
Advanced cDNA Synthesis Kit for RT-qPCR (Bio-Rad). For RT-
qPCR, mIL-33, and serpina3i were measured and normalized
to HRPT1 and RTL32. The following primers were used (5′-
3′ direction):
HPRT1-Fwd: CCTAAGATGAGCGCAAGTTGAA; HPRT1-
Rev: CCACAGGACTAGAACACCTGCTAA; RTL32-Fwd: GG
CACCAGTCAGACCGATATG; RTL32-Rev: CCTTCTCCG
CACCCTGTTG; IL-33-Fwd: GCTGCGTCTGTTGACACATT;
and IL-33-Rev: CACCTGGTCTTGCTCTTGGT. Serpina3i
primers were purchased from Bio-Rad, intron-spanning
(qMmuCID0022819), and Il1rl1 (encoding ST2) Taqman
(QuantiTect Probe PCR Kit; Mm00516117_m1) was purchased
from Applied Biosystems. Amplification reactions were
performed on the Roche Light Cycler 480. PCR reactions
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containing 5 ng/well sample cDNA were used with
1 × SsoAdvancedTM Universal SYBR R© Green Supermix
(Bio-Rad) and 250 nM primer pairs in a final volume of 5 µL.
The PCR protocol consisted of 1 cycle at 95◦C, 2 min, followed
by 44 cycles at 95◦C, 5 s; 30 s at 60◦C; and 1 s at 72◦C. Ct and Tm
were calculated by the Roche LightCycler 480 software (Roche
Molecular Systems Inc., Pleasanton, CA, United States), and the
relative expression of the genes of interest was normalized to the
expression of the reference genes HPRT1 and RTL32 in qbase+
(Biogazelle, Zwijnaarde, Belgium).
Enzymatic IL-33 Cleavage Assay
One and a half µg of recombinant activated mMCP-4 (0.1 mg/mL
in PBS) were incubated alone or with 1.5 µg (1:1 ratio), 7.5 µg
(1:5 ratio), or 15 µg (1:10 ratio) of recombinant SERPINA3I
(0.1 mg/mL in PBS) for 1 h at 37◦C; 12.5 ng of recombinant
murine IL-33 (Peprotech, 210-33, Rocky Hill, NJ, United States)
in PBS were added to each mixture and incubated again for 1 h
at 37◦C. Thereafter, samples were denatured (10 min, 95◦C with
sample buffer) under reducing conditions and loaded on a precast
gel (4–15% Mini-PROTEAN TGX Stain-Free Precast Gels, Bio-
Rad) to perform SDS-PAGE. IL-33 Western Blot was performed
as mentioned above.
Bioinformatics
Sequence variation data (release v5) from the Mouse Genome
Project (33) was used for comparative analyses of the C57BL/6N,
CBA, DBA/2, and BALB/c strains relative to the C57BL/6J
reference strain. In total, a list of 352 indels affecting the protein
coding sequence in at least one of the mouse strains was retrieved
using a custom Perl script.
Statistics
Analysis of data obtained in animal studies was performed using
the GraphPad prism version 7 software (GraphPad Software, La
Jolla, CA, United States) and one-way ANOVA or Kruskal–Wallis
test followed by Tukey multiple comparison or Dunn’s multiple
comparison tests, respectively.
RESULTS
Lack of Type 2 Airway Inflammation in
Repeatedly SplD-Exposed BALB/c Mice
C57BL/6J mice respond to repeated intratracheal applications
of SplD with key features of allergic asthma (Figure 1A).
However, BALB/c mice merely increased total BALF cell numbers
(Figure 1A). Eosinophils and neutrophils were nearly absent in
SplD-treated BALB/c mice, while C57BL/6J mice showed a strong
eosinophilic response toward SplD in the BALF (Figures 1B,C).
Goblet cell hyperplasia was not observed in SplD-treated BALB/c
mice, in contrast to C57BL/6J mice (Figure 1D). Measurable
titers of SplD-specific serum IgE could only be detected in SplD-
treated C57BL/6J mice (Figure 1E), and total IgE titers were not
different between SplD-sensitized and PBS control BALB/c mice,
while a significant up-regulation occurred in the SplD-sensitized
C57BL/6J mice (Figure 1F).
Basal and SplD-induced IL-33 mRNA levels, as determined
by quantitative RT-qPCR, were similar in the lungs of BALB/c
and C57BL/6J mice after 2 weeks of treatment with PBS
or SplD (Figure 1G). In contrast, IL-33 protein levels were
significantly elevated in SplD-treated C57BL/6J mice but did
not change significantly in BALB/c mice compared to the
PBS-treated controls (Figure 1H). Less prominent bands of
full length (30 kDa; IL-33FL) and mature IL-33 (18 kDa;
IL-33M) was observed by Western blotting in SplD-treated
BALB/c mice compared to C57BL/6J mice after 2 weeks of
treatment (Figure 1I).
Diminished Airway Inflammation in
BALB/c Mice Is Associated With Faster
IL-33 Cleavage Upon a Single
Application of SplD
IL-33 expression was measured in the lungs of C57BL/6J and
BALB/c mice 6 and 12 h after a single i.t. application of SplD. 6 h
after SplD exposure, the IL-33 mRNA levels were not significantly
increased and were comparable between C57BL/6J and BALB/c
mice. However, 12 h after SplD exposure, significantly higher
IL-33 mRNA levels were observed in BALB/c mice, while in
C57BL/6J mice a statistically insignificant trend to increased
IL-33 mRNA levels was observed (Figure 2A). In contrast to
mRNA expression, IL-33 protein levels were significantly up-
regulated in both mouse strains 6 h after a single i.t. application
of SplD. The levels were significantly decreased 12 h after
SplD application in both mouse strains compared to 6 h after
SplD exposure (Figure 2B). When comparing full length IL-
33FL of BALB/c and C57BL/6J mice after 6 and 12 h of
a single application of SplD using western blotting analysis,
there was a strong increase of IL-33FL in both strains, but in
BALB/c mice, the proteolytic processing of IL-33FL and IL-
33M was accelerated (Figure 2C). In BALB/c mice, the bands
representing IL-33FL and IL-33M were most pronounced after
6 h and declined 12 h after SplD treatment. On the contrary,
IL-33FL levels were comparable after 6 and 12 h of SplD
treatment in C57BL/6J mice, and IL-33M was increased only after
12 h (Figure 2C).
Taken together, the lower IL-33 protein amounts in BALB/c
mice at 12 h after a single application and 48 h after repeated
applications could be indicative of an increased activity protease
cleaving IL-33 in the lungs of BALB/c.
Local Administration of Recombinant
IL-33 in SplD-Treated BALB/c Mice
Restores the Allergic Response
We aimed to compensate the lack of IL-33 in BALB/c mice
by intratracheal applications of exogenous IL-33 directly after
each SplD application. After the addition of IL-33 to SplD, the
percentage of eosinophils in the BALF was significantly elevated,
while the percentage of neutrophils was decreased without major
effect on the total cell number in BALF (Figures 3A–C). The
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FIGURE 1 | Lack of type 2 airway inflammation and increased IL-33 cleavage in SplD-exposed BALB/c mice. C57BL/6J and BALB/c mice received six i.t.
applications of PBS or SplD and 48 h after the last application the samples were collected. (A) total cell count, (B) percentage of eosinophils, (C) Goblet cell count in
airways with 800–2000 µm perimeter of periodic acid–Schiff-stained lung sections, and (D) neutrophils of bronchoalveolar lavage fluid (BALF). (E) SplD-specific and
(F) total IgE measured by ELISA in sera of mice. (G) relative mRNA levels and (H) protein levels of IL-33 in lungs determined by RT-qPCR and Luminex, respectively.
(I) Western blotting of mouse lungs stained for IL-33 and β-actin. One representative blot is shown. Data are presented as mean ± SD. n = 4–15. *P < 0.05;
**P < 0.01; ***P < 0.001.
FIGURE 2 | Early degradation of IL-33 in SplD-exposed BALB/c mice. (A) mRNA levels and (B) protein levels of IL-33 6 and 12 h after PBS or SplD challenge in
lungs, determined by RT-qPCR and Luminex, respectively, and (C) western blotting of mouse lungs collected 6 and 12 h after a single application of SplD in
C57BL/6J or BALB/c mice stained for IL-33 and β-actin. One representative blot is shown. Data are presented as mean ± SD. n = 3–8. *P < 0.05; **P < 0.01.
combined treatment with SplD + IL-33 induced an up-regulation
of CD4+ T cells in the BALF, compared to the SplD or IL-33
only treatment groups (Figure 3D). The numbers of CD8+ cells
in the BALF did not significantly differ between the treatment
groups (Figure 3E). In the lungs, the percentage of eosinophils
was significantly elevated in mice that received SplD + IL-
33 compared to all control groups (Figure 3F). BALB/c mice
treated with IL-33 alone or in combination with SplD showed
elevated percentages of MHCII+CD11c+ dendritic cells in the
lungs (Figure 3G). The levels of IL-5 were below detection
levels in the lungs of BALB/c mice treated with SplD, and no
up-regulation could be seen after treatment with IL-33 or a
combination of IL-33 and SplD (Supplementary Figure 2B).
The levels of IL-4 and IL-13 also remained very low in all
experimental groups without significant difference compared
between the groups (Supplementary Figures 2A,C). SplD-
specific serum IgE (Figure 3H) and total serum IgE (Figure 3I)
were significantly up-regulated in the SplD + IL-33 group. Thus,
the addition of exogenous IL-33 could sensitize BALB/c mice to
SplD, while SplD given alone did not stimulate IgE production
in these mice. Goblet cell hyperplasia was observed in the IL-
33 only and the SplD + IL-33 groups, indicating that goblet
cell formation and mucus production are strongly dependent
on IL-33 (Figures 3J,L). IL-33 supplementation restored the up-
regulation of Il1rl1 mRNA in BALB/c mice to a comparable
degree as in C57BL/6J mice, suggesting that the rapid cleavage
Frontiers in Immunology | www.frontiersin.org 5 September 2020 | Volume 11 | Article 582044
fimmu-11-582044 September 23, 2020 Time: 16:40 # 6
Teufelberger et al. Mouse Strain-Dependent Regulation of IL-33
FIGURE 3 | Supplementation with IL-33 restores the asthmatic response and has a synergistic effect on SplD-induced allergic sensitization in BALB/c mice. BALB/c
wild-type mice were treated with six i.t. applications of PBS, SplD, IL-33 or SplD + IL-33 every second day. 48 h after the last application, mice were euthanized, and
samples were collected. (A) Total cell count and percentage of (B) eosinophils, (C) neutrophils, (D) CD4 + T cells, and (E) CD8 + T cells in the BALF were
determined by flow cytometry. Percentage of (F) eosinophils and (G) MHCII + CD11c + dendritic cells (DCs) in the lungs were determined by flow cytometry.
(H) SplD-specific IgE and (I) total IgE in sera of mice, measured by ELISA; the black line indicates the background optical density. (J) Goblet cell count in airways of
800–2000-µm perimeter in periodic acid–Schiff-stained lung sections. (K) Relative Il1rl1 mRNA expression in lungs. (L) representative images of periodic
acid–Schiff-stained lung sections. Data are presented as mean ± SD. n = 4–15. *P < 0.05; **P < 0.01; ***P < 0.001.
of IL-33 explains the absence of ST2 induction in BALB/c mice
that were treated with SplD alone (Figure 3K).
CBA and DBA/2 Mice Present a
Diminished Type 2 Response Toward
SplD While C57BL/6N Mice Are Identified
as SplD Responders
C57BL/6N, CBA, and DBA/2 mice were tested in addition to
C57BL/6J and BALB/c mice to define SplD responders and non-
responders in order to facilitate the search for the genetic cause
underlying the different inflammatory responses toward SplD.
We compared the relative magnitude of inflammatory response
parameters in different mouse strains and presented the data in
radar graphs where the highest mean value of each parameter
amongst all five tested strains was taken as one hundred percent
(Figure 4A). SplD-treated C57BL/6J mice showed the strongest
response in all measured parameters, which indicate a Th2-
biased inflammation, but not in those reflecting their neutrophil
and CD8+ T cell responses (Figure 4A). C57BL/6N mice
show a comparable reaction pattern as C57BL/6J mice upon
SplD treatment, even though the magnitude of response was
significantly reduced and the total cell numbers in BALF cells
were not increased (Figure 4B). BALB/c mice did not develop
a Th2 inflammation in response to SplD. There was, however, an
increase in CD8+ T cells, but as shown in Figure 3E, the numbers
of CD8+ T cells in the BALF were low (Figure 4C). DBA/2
mice presented with a very weak response toward SplD, which
was, however, neutrophilic rather than eosinophilic (Figure 4D).
CBA mice responded in a manner comparable to DBA/2 mice,
but neutrophil and T cell counts were lower than in the PBS
control group of this strain (Figure 4E). Goblet cell hyperplasia
was only found in SplD-treated C57BL/6J and C57BL/6N mice
(Figure 4). The data of each measured parameter of C57BL/6N,
DBA/2, and CBA mice with the statistical analysis can be
found in Supplementary Figure 1. We classified BALB/c, CBA,
and DBA/2 mice as SplD non-responder strains due to the
weak or absent type 2 inflammatory response in comparison
to C57BL/6J and C57BL/6N mice, which were defined as SplD-
responder strains.
Genome Wide Comparison of SplD
Responder and Non-responder Strains
Sequence variation data (release v5) from the Mouse Genome
Pro (33) was used for comparative analyses of the C57BL/6N,
CBA, DBA/2, and BALB/c strains relative to the C57BL/6J
reference strain. In total, a list of 352 indels affecting the
protein coding sequence in at least one of the mouse strains
was retrieved using a custom Perl script. Out of this list, 116
frameshift mutations and nine stop-codon-inducing frameshift
mutations were selected for further analysis as these mutations
Frontiers in Immunology | www.frontiersin.org 6 September 2020 | Volume 11 | Article 582044
fimmu-11-582044 September 23, 2020 Time: 16:40 # 7
Teufelberger et al. Mouse Strain-Dependent Regulation of IL-33
FIGURE 4 | C57BL/6J and C57BL/6N mice respond to SplD with key features of allergic asthma, while BALB/c, CBA, and DBA/2 mice lack a clear type 2 response.
Radar graphs, presenting relative values of measured parameters from (A) C57BL/6J, (B) C57BL/6N, (C) BALB/c, (D) DBA/2, and (E) CBA mice treated repeatedly
with PBS or SplD. Per parameter, the highest mean value between the groups was set at one hundred percent.
are expected to exert the most severe effects on the function
of the encoded proteins. These variant consequences, predicted
by the Ensembl Variant Effect Predictor (VEP), were further
investigated using CLC Main Workbench to predict if the main
transcript is affected and if the frameshift possibly affects the
function of the mutated gene product. In 20 genes, frameshift
or stop frameshift mutations were identified upstream or in their
active domain. These 20 genes were studied by literature research
to find pro- and contra-arguments for them being crucial for
the asthmatic response toward SplD (Supplementary Table 1).
Our workflow (Figure 5) allowed us to identify Serpina3i and
CXCL-11 as the most promising candidates. CXCL-11 mRNA
was not detectable by RT-qPCR in the lungs of SplD-treated
mice in any of the five mouse strains (data not shown) and was
therefore excluded.
SERPINA3I—Homology Model
Mice harbor an unusually large group of Serpina3 genes as a
result of extensive gene duplication and diversification, which in
turn encode for 13 closely related SERPINA3 protein products,
albeit with differing target specificities and biodistribution. The
high level of sequence similarity shared by murine SERPINA3
proteins essentially guarantees a highly conserved core structure.
To this end, murine SERPINA3I displays a 74% sequence identity
to SERPINA3N (Figure 6A) for which the high resolution crystal
structure is available. We harnessed the high sequence homology
of the two proteins and the available structural information
to construct a homology model for SERPINA3I (Figure 6B).
Thus, SERPINA3I is expected to adopt a fold displaying a main
central beta-sandwich consisting of two beta-sheets flanked by
a cluster of 7–9 alfa helices. This sets the structural stage for
a third beta-sheet at the top of the fold to help project the
flexible RCL. The RCL contains an enzyme cleavage site (P1-
P1’), which is located at the C-terminus of the protein. RCL
is expected to be cleaved by a target protease at P1 and P1’,
leading to its covalent attachment via the main carbonyl carbon
of the P1 residue of the SERPINA3I. This would be expected to
establish a stable complex between SERPINA3I and a protease,
such as mMCP-4 leading to the inhibition of mMCP-4. The
frameshift mutation in serpina3i was stated in the sanger mouse
genome sequencing database (rs242560633). The sequence lacks
a cytosine at bp747, which results in a frameshift at residue
Cys249 and a stop codon after residue 251. As the RCL starts
at G357 (31), the mutated Serpina3i is predicted to result in
an unfunctional protein. In C57BL/6J and C57BL/6N mice,
SERPINA3I is predicted to be full length, comprising 408 amino
acids (NP_001186869.1).
To obtain insights into the structural and functional
consequences of the identified frameshift mutation, we compared
the sequences of full-length and truncated SERPINA3I to the
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FIGURE 5 | Workflow scheme for the identification of the relevant gene(s) responsible for asthma development upon SplD exposure. Genomes of SplD responders
(C57BL/6J and C57BL/6N mouse strains) were compared to the genomes of SplD non-responders (BALB/c, CBA and DBA/2 mouse strains). The indels specific for
SplD responders were further analyzed for their consequence on the gene product, and the frameshift mutations were selected as the mutations affecting protein
function the most.
closely related SERPINA3N (Figure 6A) and constructed a
homology model of SERPINA3I based on the crystal structure
of the mouse SERPINA3N (34) (Figure 6B). Our analyses
illustrate that the predicted protein product of Serpina3i in
mouse strain BALB/c would display a debilitating sequence
truncation from Cys259 onward that includes the RCL and
would prevent the protein from folding to a functional form
(Figures 6A,B). Thus, the observed deletion would ultimately
cause deficiency in SERPINA3I in BALB/c mice and other mouse
strains bearing the same mutation. A public online tool1 is
available to analyze different mouse strains having the same
Serpina3i frameshift mutation (35). Gene expression of Serpina3i
in mouse lungs collected 6 h after a single i.t. application
1http://bioit2.irc.ugent.be/prx/mousepost/Home.php
of PBS or SplD showed no significant up-regulation in SplD-
treated mice. Furthermore, Serpina3i mRNA was up-regulated in
response to IL-33 + SplD treatment in BALB/c mice suggesting
a possible involvement of SERPINA3I in IL-33 signaling or
regulation (Figure 7A). In other mouse strains, no difference in
gene expression of Serpina3i after a single i.t. application SplD
was observed. Importantly, the observed difference in Serpina3i
gene expression difference does not fully reflect the observed
phenotypic difference since a truncation of the gene in the non-
responder mouse strains BALB/c, CBA, and DBA/2 would result
in an unfunctional protein.
SERPINA3I Decelerates IL-33
Degradation via mMCP-4
To test the functional activity in vivo, recombinant full-length
SERPINA3I was administered intratracheally directly after SplD
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FIGURE 6 | Protein sequence alignment of murine SERPINA3N and SERPINA3I from C57BL/6J and BALB/c mice and structural mapping of SERPINA3I deficiency
in BALB/c mice. (A) Alignment of the sequences of murine SERPINA3N (Uniprot sequence Q91WP6) and the sequences for SERPINA3I from mouse strains
C57BL/6J and BALB/c. The sequence segment absent in BALB/c SERPINA3I as a result of the frameshift mutation at Cys249 and the introduction of a stop codon
after residues 251 is colored in red. The reactive center loop (RCL) locates within the deleted sequence and is colored in orange. (B) Cartoon representation of a
predicted model for murine SERPINA3I based on the crystal structure of murine SERPINA3N (Horvath et al. 2005) as computed by the program RaptorX (Källberg
et al. 2012). The figure was produced with PyMOL v. 2.3.0.
FIGURE 7 | Serpina3i mRNA expression is up-regulated in mouse lungs upon SplD and IL-33 exposure and decelerates IL-33 degradation in vivo and in vitro.
(A) relative mRNA expression of Serpina3i in lungs 6 h after a single i.t. application of PBS or SplD in C57BL/6J, C57BL/6N, DBA/2, CBA, and BALB/c mice as well
as BALB/c mice 6 h after IL-33 or SplD + IL-33 i.t. treatment determined by RT-qPCR. Relative mRNA levels determined by RT-qPCR of IL-33 (B) and Il1rl1
(D) determined by RT-PCR. IL-33 protein determined by (C) Luminex and (E) Western blot in mouse lungs of BALB/c mice 12 h after PBS, SplD, SERPINA3I, or
SplD + SERPINA3I treatment. Data are presented as mean ± SD. n = 5–9. (F) IL-33 Western blot of recombinant mature murine IL-33 (20 kDa) co-incubated with
mMCP-4 for 1 h with and without 1 h preincubation with increasing concentrations of SERPINA3I. One representative blot of three independent experiments is
shown. *P < 0.05; **P < 0.01.
to BALB/c mice. SERPINA3I treatment did not cause any up-
regulation of IL-4, IL-5, or IL-13 in the lungs of BALB/c mice
(Supplementary Figures 2D–F), while, IL-33FL and IL-33M
protein levels were significantly higher in the lungs of mice
receiving SplD + SERPINA3I than when SplD was administered
alone (Figure 7C). As expected the IL-33 and Il1rl1 mRNA
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expression levels were not significantly changed (Figures 7B,D).
The analysis of the cleavage bands of IL-33 by Western blot
revealed that both IL-33FL and IL-33M were increased in
SplD + SERPINA3I-treated mice (Figure 7E). These results
indicate that SERPINA3I can decelerate the degradation of IL-
33FL that was induced by in vivo application of SplD. Moreover,
preincubation of mMCP-4 with SERPINA3I prevents mMCP-4-
induced enzymatic degradation of recombinant murine IL-33M
in a dose-dependent manner (Figure 7F).
DISCUSSION
In this study, we have demonstrated that the allergic response
toward the S. aureus protease SplD is mouse strain dependent.
Our data suggest that rather than differences in S. aureus
strains, the genetic variability of the host could be an important
determinant of the immune response to Spls in human S. aureus
carriers. In humans that are naturally exposed to S. aureus, the
quality of the Spl-specific antibody and T-cell response is strongly
biased toward a Th2 profile on average with extensive variation
between individuals (3). This could partially be explained by
differences in exposure to Spls, which are encoded in around
80% of clinical S. aureus isolates. Our data, however, suggest
that genetic differences affecting the posttranslational IL-33
regulation could also play a role.
While C57BL/6J and C57BL/6N mice show typical features
of allergic asthma, this response is lacking or significantly
diminished in BALB/c, CBA, and DBA/2 mouse strains. C57BL/6
and BALB/c mice have often been referred to as Th1-prone
or Th2-prone strains, respectively (36). In striking contrast,
C57BL/6 mice presented a higher eosinophilic Th2-biased
response than BALB/c mice in our SplD sensitization model.
A stronger eosinophilic response in C57BL/6 mice compared
to BALB/c mice has been described previously in other murine
asthma models using OVA/alum, house dust mite extract
or the house dust mite allergen Der p 1 (37–40). In the
mentioned models, however, BALB/c mice still developed a weak
eosinophilic response, which might be due to the activation of
other pathways next to the IL-33/ST2 signaling axis. We have
shown previously that the type 2 inflammatory response toward
SplD and lung infiltration with IL-13+ type innate lymphoid
cells and IL13+ CD4+ T cells in C57BL/6J mice is mainly
mediated by IL-33 (4). In this study, we found that C57BL/6J and
BALB/c mice also differ in their post-translational regulation of
IL-33. A single intratracheal application of SplD caused an up-
regulation of IL-33 in both mouse strains after 6 h; however,
IL-33 was degraded more rapidly in BALB/c than in C57BL/6J
mice. In line with these results, C57BL/6 mice responded to
long-term exposure to SplD with significantly increased Il1rl1
expression, while this was not the case in BALB/c mice. We
excluded an impairment in ST2 expression downstream of IL-
33 in BALB/c mice, because the administration of IL-33 restored
the up-regulation of Il1rl1 and, in combination with SplD, led
to a strong eosinophilic response in BALB/c mice. Our observed
mouse strain dependence of the phenotype in the SplD asthma
model illustrates the importance of the genetic background when
testing a potential allergen in mice (Figure 8). The observed loss
of function mutation in Serpina3i could also explain other mouse
strain-dependent differences in allergic asthma, which have
previously been reported. Genetic differences in the regulation
of IL-33 could be determinants of allergic sensitization or
FIGURE 8 | The role of SERPINA3I in the IL-33 regulation mechanisms in C57BL/6J and BALB/c mice upon SplD exposure. SplD administration to the murine
airway mucosa causes IL-33 release from alveolar epithelial cells type 2 (AECIIs), and Serpina3i up-regulation in the lungs. In the lungs, IL-33 triggers mast cells to
release murine mast cell protease 4 (mMCP-4), which can degrade IL-33. In C57BL/6J mice, functional SERPINA3I is present; it inhibits mMCP-4 and thereby
prevents IL-33 degradation (shown in vitro). As a result, IL-33 triggers a type 2 inflammatory response via the IL-33/ST2 axis. BALB/c mice lack a functional
SERPINA3I protein due to a mutation. Consequently, SplD-triggered IL-33 is degraded, and no type 2 inflammation is triggered. In BALB/c mice the administration of
an active form of recombinant IL-33 in excess additionally to SplD is leading to an inflammatory response comparable to C57BL/6J mice since the degradation of
IL-33 can be circumvented to the degree that the IL-33/ST2 signaling can take place.
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severity of airway diseases. In humans there are several single-
nucleotide polymorphisms (SNPs) upstream of the IL-33 gene,
which are associated with asthma prevalence (41); however, the
functional consequences of these SNPs is largely unknown. The
human SERPINA3 gene has expanded by gene duplication into
a cluster of 14 equivalent mouse SERPINA3 genes, Serpina3a-
n. Based on protein expression patterns, especially in the brain,
Serpina3n is considered as the murine orthologue of the human
SERPINA3 (31, 34). The murine SERPINA3N is known to
inhibit leukocyte elastase and cathepsin G (34), but the mast cell
chymase inhibitory function of α-1 anti-chymotrypsin, however,
could potentially be conserved in SERPINA3I and could explain
our observed mechanism. Mutations in SERPINA3 have been
described to have an impact in lung diseases. An association
between childhood onset asthma and a 1.4 kb gain mutation
downstream of SERPINA3 has been reported (42). Mutations in
SERPINA3 leading to decreased α-1 anti-chymotrypsin serum
levels were associated with the inflammatory lung diseases COPD
and emphysema (43). Our study revealed a novel IL-33 regulation
pathway of SERPINA3I inhibiting the IL-33 degrading mast cell
chymase mMCP-4, which could be, with the equivalent human
proteins, of general importance in allergic airway diseases (44).
The human SERPINA3 is a known mast cell chymase inhibitor
and could thus be relevant in IL-33 regulation (45).
The study of individual differences in this protease-serpin
interaction network may help to identify predictive biomarkers
for Th2-biased airway disease development, especially in
individuals colonized by S. aureus.
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Supplementary Figure 1 | Inflammatory profile of C57BL/6N, DBA/2 and CBA
mice upon repeated intratracheal applications of PBS or SplD for 2 weeks. (A)
Total cell count, (B) percentage of eosinophils, (C) neutrophils, (D) CD4+ T cells,
and (E) CD8 + T cells in the BALF analyzed by flow cytometry. (F) Total cell count
of local draining lymph nodes, (G) total, and (H) SplD-specific IgE in serum
measured by ELISA. (I) Goblet cells in airways with a perimeter of 800–2000 µm,
analyzed in periodic acid–Schiff-stained lungs. (J) IL-33 protein levels in lungs
measured by Luminex. (K) Relative Il1rl1 mRNA expression in lungs. Data are
presented as mean ± SD. n = 4–6.
Supplementary Figure 2 | Analysis of type-2 cytokines in the lung homogenates
of mice by Luminex. The levels of IL-4 (A), IL-5 (B), and IL-13 (C) cytokines in the
lungs of C57BL/6J, and BALB/c mice treated with six i.t. applications of PBS,
SplD, IL-33, or SplD + IL-33 every second day for 2 weeks. The lung
homogenates of BALB/c mice after 12 h after a single i.t. application of PBS,
SplD, SERPINA3I, or SplD + SERPINA3I treatment were analyzed for IL-4 (D), IL-5
(E), and IL-13 (F). Data are presented as mean ± SD. n = 6. The limit of detection
of each cytokine is indicated by a dotted line.
Supplementary Table 1 | A list of mutated genes between SplD-responder and
non-responder strains. Mutation, predicted consequence for the protein function,
pro- and contra arguments for being a candidate gene responsible for asthma
development according to literature research.
Supplementary Table 2 | A summary of experimental procedures per figure.
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